Tag: targeted cancer therapy
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
— Heat-triggered release mechanism unequivocally confirmed
— Favorable safety profile with good tolerability
— Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS)
— One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion
Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). Read more…
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
— Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3
Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after the independent Data Safety Monitoring Board (DSMB) declared dose level 2 (DL2) as safe and recommended escalation to the final dose level (DL3). In the trial, the Company’s lead compound THE001is tested in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS) in combination with regional hyperthermia. Read more…
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
— THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activity
— Data presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024
Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS). The data were presented as a poster (#P410) titled “Phase I study of THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in patients with locally advanced or metastatic soft tissue sarcoma” at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 in San Diego, USA. Read more…
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
– Leading European T cell therapy researcher adds further scientific expertise
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Prof. Dr. Chiara Bonini to its Scientific Advisory Board.
Prof. Dr. Chiara Bonini is Professor of Hematology at the Università Vita-Salute San Raffaele, School of Medicine, and Deputy Director of the Research Division of Immunology, Transplantation and Infectious Diseases at the San Raffaele Scientific Institute (Milan, Italy). Read more…